Forte Biosciences Inc
Veridion Score
Composite trend over time
Why is FBRX moving today?
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for FBRX.
FBRX insider activity
Forte Biosciences Inc
No multi-insider buying cluster in the last 90 days
Net buying: $234K across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-04-03 | 2026-04-01 | Wagner Paul A. | Insider | sell | $24.86 | 98 | 84,330 | $2K | SEC Form 4 |
| 2026-04-03 | 2026-04-01 | Riley Antony A | Insider | sell | $24.86 | 134 | 41,982 | $3K | SEC Form 4 |
| 2026-01-02 | 2026-01-01 | Wagner Paul A. | Insider | sell | $27.27 | 164 | 83,178 | $4K | SEC Form 4 |
| 2026-01-02 | 2026-01-01 | Riley Antony A | Insider | sell | $27.27 | 154 | 41,741 | $4K | SEC Form 4 |
| 2026-01-02 | 2025-12-30 | Riley Antony A | Insider | buy | $26.33 | 9,680 | 41,520 | $255K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 4 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moFBRX contract awards, year to date.
Public federal awards linked to this ticker.
FBRX lobbying filings, year to date.
Registered lobbying filings matched to Forte Biosciences Inc.